Corneal graft rejection – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:53:16 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Corneal graft rejection – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Dexamethasone and Fluorometholone for Patients Undergoing Corneal Transplantation https://clinicaltrials.eu/trial/study-on-dexamethasone-and-fluorometholone-for-patients-undergoing-corneal-transplantation/ Wed, 29 Apr 2026 14:25:16 +0000 https://clinicaltrials.eu/trial/study-on-dexamethasone-and-fluorometholone-for-patients-undergoing-corneal-transplantation/ This clinical trial is focused on studying treatments for patients undergoing corneal transplantation, specifically a procedure known as Descemet’s Membrane Endothelial Keratoplasty (DMEK). The study will evaluate two different eye drop medications: Dexamethasone and Fluorometholone. Dexamethasone is used in the form of a solution called “Dexamethason 1 mg/ml Teva, oogdruppels,” while Fluorometholone is used as a suspension known as “FML Liquifilm 0.1% w/v Sterile Eye Drops Suspension.”

The purpose of the study is to assess a treatment plan that aims to reduce the risk of increased eye pressure and loss of cells in the cornea after the DMEK procedure. Participants will be randomly assigned to receive either the Dexamethasone or Fluorometholone eye drops, or a placebo. The study will monitor the effects of these treatments over a period of up to two years, with regular check-ups to observe any changes in eye pressure and corneal health.

Throughout the study, researchers will also gather information on the overall health of the eye, including vision quality and patient satisfaction. The goal is to find the most effective way to support patients’ recovery and maintain the health of the transplanted cornea. This trial will help determine the best approach to minimize complications and improve outcomes for individuals undergoing corneal transplantation.

]]>